Kronos Bio (KRON) Stock Price, News & Analysis

Company Overview

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision therapeutics for patients with cancer. Founded in 2018 and based in Cambridge, Massachusetts, Kronos Bio applies its proprietary functional genomics platform to identify and validate vulnerabilities in transcriptional and epigenetic regulation that drive tumor growth. By integrating advanced screening technologies, the company aims to accelerate target identification and optimize small-molecule drug candidates with high potency and selectivity.

The company’s lead programs focus on selective inhibitors of cyclin-dependent kinase 9 (CDK9), a critical regulator of gene expression in cancer cells, and novel modulators of transcriptional machinery that have demonstrated the potential to overcome resistance mechanisms associated with existing therapies. Kronos Bio’s pipeline includes clinical-stage candidates that have entered early-phase studies in the United States, with plans to expand into European centers to evaluate safety, pharmacodynamics and preliminary efficacy in multiple hematological and solid tumor indications.

Kronos Bio’s research and development efforts are supported by a team of experienced industry leaders and scientific founders with deep expertise in oncology drug discovery and translational medicine. The leadership team is committed to advancing a disciplined clinical strategy, leveraging biomarker-driven patient selection to maximize therapeutic benefit and inform subsequent trial design. Strategic collaborations with academic institutions and contract research organizations enable Kronos Bio to maintain flexibility in resource allocation while driving programs toward key value-inflection milestones.

With a focus on precision oncology and a growing clinical portfolio, Kronos Bio is positioned to address high unmet medical needs in cancer treatment. The company’s approach reflects an emphasis on rigorous target validation, translational research and biomarker development, all aimed at delivering innovative therapies that can improve long-term outcomes for patients facing aggressive malignancies.

Key Stats

• Today's Range: $0.87 to $0.88
• 50-Day Range: $0.67 to $0.89
• 52-Week Range: $0.65 to $1.60
• Volume: 54,089 shs
• Average Volume: 367,094 shs
• Market Capitalization: $53.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.63
• Consensus Rating: Hold

Kronos Bio Stock Analysis - MarketRank™

Kronos Bio scored higher than 56% of companies evaluated by MarketBeat, and ranked 495th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Kronos Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kronos Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kronos Bio are expected to grow in the coming year, from ($1.36) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kronos Bio is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kronos Bio is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kronos Bio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.91% of the float of Kronos Bio has been sold short.

Short Interest Ratio / Days to Cover

Kronos Bio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kronos Bio has recently increased by 37.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kronos Bio does not currently pay a dividend.

Dividend Growth

Kronos Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.91% of the float of Kronos Bio has been sold short.

Short Interest Ratio / Days to Cover

Kronos Bio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kronos Bio has recently increased by 37.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Kronos Bio this week, compared to 1 article on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kronos Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,609.00 in company stock.

Percentage Held by Insiders

24.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KRON Stock Analysis - Frequently Asked Questions

How have KRON shares performed this year?

Kronos Bio's stock was trading at $0.95 at the beginning of 2025. Since then, KRON stock has decreased by 7.4% and is now trading at $0.88.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) announced its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The business had revenue of $2.27 million for the quarter, compared to analysts' expectations of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kronos Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRON
• CIK: 1741830
• Web: kronosbio.com
• Phone: 650-781-5200
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kronos Bio: $1.63
• High Price Target: $2.25
• Low Price Target: $1.00
• Potential Upside/Downside: +84.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.08 million
• Net Margins: -701.53%
• Pretax Margin: -701.53%
• Return on Equity: -64.22%
• Return on Assets: -47.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.93
• Quick Ratio: 12.93

Sales & Book Value

• Annual Sales: $9.85 million
• Price / Sales: 5.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.45 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 61,050,000
• Free Float: 46,155,000
• Market Cap: $53.72 million
• Optionable: Optionable
• Beta: 1.64